ConductScience.org, home

Paper4353012

A clinicopathologic analysis of adriamycin cardiotoxicity.

Lefrak EA and 3 others. Cancer, 1973. Cited by 1,453 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. A clinicopathologic analysis of adriamycin cardiotoxicity. Papers, record 4353012. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4353012

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A clinicopathologic analysis of adriamycin cardiotoxicity.
PubMed
Journal
Cancer
PubMed
Year
1973
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1,453
iCite
Relative citation ratio, by iCite
35.2
iCite
Revised in PubMed
2022-04-09
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lefrak EAE A
2Pitha JJ
3Rosenheim SS
4Gottlieb JAJ A

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DoxorubicinMajor topic
HeartMajor topic
Heart FailureMajor topic
Adult
Autopsy
Electrocardiography
Female
Heart Conduction System
Heart Diseases
Heart-Lung Machine
Humans
Inclusion Bodies
Male
Middle Aged
Mitochondrial Swelling
Myocardium
Neoplasms

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03342300Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue SarcomaBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by421

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,453 citations.

PMIDTitleJournalYearIn PapersSource
42890782microRNA-15b modulates stress-induced premature senescence in chronic doxorubicin cardiomyopathy.Front Pharmacol2026https://conductscience.org/library/papers/42890782PubMed
42787435Phytomedicines modulate pyroptosis in cardiovascular diseases: pre-clinical evidence, limitations and translational perspectives.Front Pharmacol2026https://conductscience.org/library/papers/42787435PubMed
42525154L-Arginine effectively alleviates doxorubicin-induced cardiac dysfunction by inhibiting myocardial fibrosis.Mol Biol Rep2026https://conductscience.org/library/papers/42525154PubMed
42499264The Relationship Between Physical Activity and Left Ventricular Remodeling in Childhood Cancer Survivors Treated With Anthracyclines: A Cross-Sectional Study.Pediatr Blood Cancer2026https://conductscience.org/library/papers/42499264PubMed
42485715Mortality in Patients With Hodgkin Lymphoma and Heart Failure: A Swedish Population-Based Study.JACC Adv2026https://conductscience.org/library/papers/42485715PubMed
42135753HER2-targeted doxorubicin-loaded cell-derived extracellular vesicles induce apoptosis of breast cancer cells via ROS/TXNIP pathway activation.Cancer Cell Int2026https://conductscience.org/library/papers/42135753PubMed
42110553Targeting SIRT1 stability: arctiin ameliorates doxorubicin-induced cardiac injury by inhibiting SMURF2 binding and enhancing protective lipid metabolism.Front Pharmacol2026https://conductscience.org/library/papers/42110553PubMed
42057146Regulation of Endoplasmic Reticulum Stress by Empagliflozin in Doxorubicin-Induced Cardiotoxicity in Rats.J Cell Mol Med2026https://conductscience.org/library/papers/42057146PubMed
42038031Deciphering Cancer Therapy-Induced Cardiotoxicity in the Era of Spatial and Multi-Omics from Systemic Mechanisms to In Situ Microenvironments.J Cancer2026https://conductscience.org/library/papers/42038031PubMed
42022755Doxorubicin exposure leads to cardiac fibroblast dysregulation and worsens fibrotic remodeling in the pathological heart.J Mol Cell Cardiol Plus2026https://conductscience.org/library/papers/42022755PubMed
42003118The PI3K-AKT-VEGF Signaling Pathway Contributes to Doxorubicin-induced Chemotherapy-related Cognitive Impairment.Curr Neuropharmacol2026https://conductscience.org/library/papers/42003118PubMed
41984837PPP1R3G-RIPK1-ZBP1 axis activates early-stage apoptosis and late-stage necroptosis to promote doxorubicin-induced cardiotoxicity.Proc Natl Acad Sci U S A2026https://conductscience.org/library/papers/41984837PubMed
41977162Cardiotoxicity of Antitumor Agents: Therapeutic Challenges in Heart Failure with Reduced and Preserved Ejection Fraction.Int J Mol Sci2026https://conductscience.org/library/papers/41977162PubMed
41924873Safety and Treatment Efficacy of Systemic, Locoregional, and Nanoparticle Encapsulated Anthracycline Chemotherapy: Insights Into Cardiotoxicity.Arterioscler Thromb Vasc Biol2026https://conductscience.org/library/papers/41924873PubMed
41845066Short-term blockade of E-prostanoid 3 receptor mitigates necroinflammation and ameliorates ischemia/reperfusion- and doxorubicin-induced acute myocardial injury.Basic Res Cardiol2026https://conductscience.org/library/papers/41845066PubMed
41637561Incidence, timing, and prognosis of heart failure after treatment for large B-cell lymphoma in Sweden during 2007-2022.Blood Adv2026https://conductscience.org/library/papers/41637561PubMed
41584283Cancer therapy-related cardiovascular aging: mechanisms, monitoring, and intervention strategies.Front Cardiovasc Med2025https://conductscience.org/library/papers/41584283PubMed
41508006Soluble neprilysin is associated with myocardial damage and systolic dysfunction in an animal model of doxorubicin-induced cardiotoxicity.Cardiooncology2026https://conductscience.org/library/papers/41508006PubMed
41206057Association of early dexrazoxane with reduced cardiotoxicity risk in sarcoma patients treated with anthracycline chemotherapy.Oncologist2025https://conductscience.org/library/papers/41206057PubMed
41128656First-line Anlotinib plus Anthracyclines and Ifosfamide Followed by Anlotinib Maintenance in Advanced Soft-Tissue Sarcoma: A Phase II Single-Arm Trial.Clin Cancer Res2026https://conductscience.org/library/papers/41128656PubMed

See all 421 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/4353012

GET https://conductscience.org/api/papers/v1/4353012/cited_by?page=2